Table 1.
Characteristics of studies included in the analysis
| Study (Year) | Publication | Cohort Descriptiona | N | Treatment Period (weeks) | Dialysis | Target Hb/Hct | Hemoglobin, mean g/dl (SD)
|
SBP, mean mmHg (SD)
|
DBP, mean mmHg (SD)
|
LVMi, mean gm/m2 (SD)
|
Δ LVMi | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Final | Baseline | Final | Baseline | Final | Baseline | Final | ||||||||
| Cannella (1990) | Clin Nephrol | Treated | 9 | 26 | Y | 10 g/dl | 5.9 (1.30) | 10.2 (1.30) | 115 (17) | 112 (19) | 70 (5) | 73 (14) | 115 (17) | 78 (14) | −37 |
| Pascual (1991) | Clin Nephrol | (i) Hypertensive | 8 | 52 | Y | 30-35% | 159 (7) | 145 (12) | 96 (8) | 87 (9) | 235 (40) | 168 (51) | −67.2 | ||
| (ii) Normotensive | 7 | 52 | Y | 30-35% | 6.4 (0.90) | 10.5 (0.90) | 133 (10) | 122 (11) | 82 (10) | 75 (9) | 183 (43) | 107 (24) | −75.8 | ||
| Portoles (1997) | Kidney Int | Treated | 11 | 26 | N | 35% | 9 (1.0) | 11.7 (1.30) | 144 (32.5) | 147.2 (31.2) | 76.0 (20.90) | 81.1 (15.3) | 178 (68) | 147 (68) | −30.9 |
| Massimetti (1998) | Blood Purif | Treated | 11 | 65 | Y | 30-35% | 8.4 (0.80) | 10.9 (1.20) | 155 (12) | 154 (24) | 87 (7) | 85 (9) | 186 (56) | 189 (39) | 3 |
| Foley (2000) | Kidney Int | (i) CLVH / Lower Hb | 36 | 48 | Y | 9.5-10.5 g/dl | 10.1 (0.60) | 10.5 (1.20) | 157 (11.8) | NA | 81 (8.9) | NA | 139 (25) | 145.1 (NA) | 6.1 |
| (ii) CLVH / Higher Hb | 34 | 48 | Y | 13-14 g/dl | 10.0 (0.90) | 12.8 (1.10) | 162 (12.9) | NA | 82 (7.2) | NA | 147 (26) | 148.1 (NA) | 1.1 | ||
| (iii) LVD / Lower Hb | 37 | 48 | Y | 9.5-10.5 g/dl | 10.0 (0.60) | 10.7 (1.00) | 155 (15) | NA | 82 (9.0) | NA | 165 (50) | 160 (NA) | −5.1 | ||
| (iv) LVDc / higher Hb | 39 | 48 | Y | 13-14 g/dl | 10.3 (0.60) | 12.8 (2.20) | 154 (18.5) | NA | 84 (9.3) | NA | 172 (36) | 166 (NA) | −5.8 | ||
| Hayashi (2000) | Am J Kidney Dis | Partial Hct correctionb | 9 | 16 | N | 30% | 7.9 (0.5)c | 10.7 (0.6)c | 147.8 (23.1) | 151.3(22.8) | 74.2 (14.70) | 76.5(7.8) | 141 (36) | 127 (30) | −13.7 |
| London (2001) | J Am Soc Nephrol | Treated | 153 | 54 (37)d | Y | 10-11 g/dl | 8.7 (1.70) | 10.5 (1.50) | 169.4 (29.7) | 146.7 (29) | 90.2 (15.60) | 78 (14) | 174 (45) | 162 (45) | −12 |
| Sikole (2002) | Artificial Organs | Treated | 14 | 52 | Y | 30-35% | 7.9 (1.40) | 10.0 (1.00) | NAe | NAe | NAg | NAg | 172 (29) | 129 (26) | −43.4 |
| Frank (2004) | Kidney Int | Treated | 23 | 28 | Y | 12.5 g/dl | 10.5 (0.90) | 13.4 (3.10) | 132 (4) | 128 (3) | 76 (2) | 73 (2) | 134 (26) | 97 (25) | −37 |
| Roger (2004) | J Am Soc Nephrol | (i) Lower Hb | 78 | 104 | Mixedf | 9-10 g/dl | 11.2 (0.80) | 10.8 (1.30) | 137 (18) | 133 (20) | 81 (10) | 77 (11) | 101 (23) | 105 (24) | 4 |
| (ii) Higher Hb | 74 | 104 | Mixedf | 12-13 g/dl | 11.2 (0.90) | 12.1 (1.40) | 139 (19) | 138 (23) | 80 (11) | 79 (12) | 105 (23) | 107 (25) | 2 | ||
| Ayus (2005) | Kidney Int | Treated | 40 | 26 | N | 12 g/dl | 9.1 (0.70) | 11.3 (1.90) | 148 (21) | 146 (18) | 82 (11) | 81 (9) | 157 (56) | 142 (56) | −15 |
| Hampl (2005) | Kidney Blood Press Res | Treated | 230 | 229 | Y | 13.5-14.5 g/dl | 11.2 (2.20) | 14.1 (1.40) | 165 (8) | 130 (10) | 92 (8) | 80 (5) | 159 (50.4) | 130.2 (42.7) | −28.8 |
| Levin (2005) | Am J Kidney Dis | (i) Lower Hb | 74 | 104 | Mixedf | 9-10.5 g/dl | 11.7 (0.80) | 11.4 (NA) | 140.5(18.6) | 133.4 (NA) | 79.6 (10.50) | 75.1 (NA) | 98 (25) | 104 (NA) | 5.2 |
| (ii) Higher Hb | 78 | 104 | Mixedf | 12-14 g/dl | 11.8 (0.80) | 12.7 (NA) | 137.1(17.5) | 133.9 (NA) | 75.8 (11.50) | 75.6 (NA) | 101 (22) | 101 (NA) | 0.4 | ||
| Parfrey (2005) | J Am Soc Nephrol | (i) Lower Hb | 300 | 96 | Y | 9.5-11.5 g/dl | 11.0 (1.20) | 10.9 (1.20) | 140 (20) | 139 (22) | 80 (12) | 79 (14) | 112 (33) | 128 (40) | 16.3 |
| (ii) Higher Hb | 296 | 96 | Y | 13.5-14.5 g/dl | 11.0 (1.20) | 13.3 (1.50) | 144 (21.65) | 141 (22.14) | 81 (11.48) | 80 (12.57) | 117 (36) | 128 (43) | 11.8 | ||
| Ritz (2007) | Am J Kidney Dis | (i) Lower Hb | 82 | 60 | Mixedf | 10.5-11.5 g/dl | 11.7 | 12.1 (NA) | 133 (NA) | 134 (NA) | 80 (NA) | 80 (NA) | 116 (35) | 117 (36) | 0.5 |
| (ii) Higher Hb | 88 | 60 | Mixedf | 13-15 g/dl | 11.9 | 13.5 (NA) | 134 (NA) | 134 (NA) | 78 (NA) | 76 (NA) | 114 (31) | 112 (33) | −1.2 | ||
Y, yes; N, no; CLVH, concentric left ventricular hypertrophy; LVD, left ventricular dilation.
Reporting only for cohorts treated with EPO.
Same study cohort evaluated at two targets. Only the results for partial-correction are reported here.
Hematocrit has been converted to hemoglobin by dividing by 3.
By patient, mean (SD).
Mean arterial pressure increased from 114.7 ± 13.9 at baseline to 119.3 ± 13.8 mmHg at end of treatment period (where mean arterial pressure = diastolic arterial pressure + [systolic arterial pressure + diastolic arterial pressure]/3).
These cohorts are classified as CKD for the purpose of this analysis. The following are numbers of patients who commenced dialysis during the study period: 15 out of 78, Roger 2004 (i); 24 out of 74, Roger 2004 (ii); 8 out of 74, Levin 2005 (i); 11 out of 78, Levin 2005 (ii); 3 out of 82, Ritz 2007 (i); and 2 out of 88, Ritz 2007 (ii).